Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia

Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia: A Randomized, Double-blind Clinical Trial

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05296863

Enrollment

Registered

2022-03-25

Start date

2021-10-11

Completion date

2021-12-03

Last updated

2022-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia, Androgenetic, Hair Loss/Baldness

Keywords

Stem cell therapy, Adipose derived stem cell conditioned media, Hair regeneration

Brief summary

This study investigated the efficacy of adipose derived stem cell conditioned media (ADSC-CM) combined with minoxidil for hair regeneration therapy in male AGA.

Detailed description

This study was a double-blind, randomized clinical trial (RCT). Two concentrations of ADSC-CM were utilized: concentrated and non-concentrated ADSC-CM. The scalp was divided vertically in half; one side was injected with 2 ml of ADSC-CM, while the control side received 2 ml of NaCl 0,9%. After the injection, patients applied topical 5% minoxidil twice daily. Clinical improvements were assessed using photographic evaluation and trichoscan every two weeks.

Interventions

COMBINATION_PRODUCTNon-concentrated adipose-derived stem cell conditioned media and 5% Minoxidil

Non-concentrated ADSC-CM is given during week 0, 2, 4, and 6 on the left side of the scalp. Minoxidil is applied twice using a spray, in the morning and at night.

COMBINATION_PRODUCTConcentrated adipose-derived stem cell conditioned media and 5% Minoxidil

Intervention is given during week 0, 2, 4, and 6 on the left side of the scalp. Minoxidil is applied twice using a spray, in the morning and at night.

COMBINATION_PRODUCTPlacebo and 5% Minoxidil

Intervention is given during week 0, 2, 4, and 6 on the right side of the scalp. Minoxidil is applied twice using a spray, in the morning and at night.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

MALE

Age

25 Years to 58 Years

Healthy volunteers

Yes

Inclusion criteria

* males aged 25-58 years old * Hamilton-Norwood criteria grades II to VI * cessation of anti-androgens and minoxidil treatment for at least one month

Exclusion criteria

* patients with hair loss other than AGA, such as alopecia areata, chemotherapy-induced alopecia, autoimmune-induced alopecia, and scalp malignancies; * patients receiving 5-alpha reductase inhibitor therapy; * patients who had received growth factor treatment (platelet-rich plasma or microneedling) for at least six months prior to the study; and * history of hypertrophic scars or blood clotting disorders.

Design outcomes

Primary

Measure	Time frame	Description
Hair count	Within 6 weeks	Sum of hair
Mean thickness	Within 6 weeks	In centimeters
Total follicular units	Within 6 weeks	Unit of hair follicles
Vellus rate	Within 6 weeks	Percentage of terminal hairs
Hair density	Within 6 weeks	count/cm2
Terminal rate	Within 6 weeks	Percentage of terminal hairs

Secondary

Measure	Time frame	Description
7-point scale	Within 6 weeks	In order to assess patient satisfaction of the research process and treatment outcome

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026